An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon- β1 and fingolimod therapy

This study aims to compare NK cells obtained from multiple sclerosis (MS) patients receiving interferon- β1 and fingolimod therapies. Fingolimod reduced the CD56bright NK cell subset. The remaining CD56dim NK cells displayed NKG2D, NKp46, CD107a, and IFN-γ levels similar to those from the patients under interferon-β1 therapy. Alternatively, comparative transcriptomics and pathway analyses revealed s ignificant distinctions between two therapy modalities. Molecular signature of the CD56dim NK cells from fingolimod-treated MS patients was closely associated to those from healthy subjects.

Source: Journal of Neuroimmunology - July 28, 2020 Category: Allergy & Immunology Authors: Nazire Pinar Acar, Asli Tuncer, Didem Ozkazanc, Feyza Gul Ozbay, Beren Karaosmanoglu, Sibel Goksen, Guliz Sayat, Ekim Z. Taskiran, Gunes Esendagli, Rana Karabudak Source Type: research